Gavilimomab Biosimilar – Anti-BSG, CD147 mAb – Research Grade

Description of Gavilimomab Biosimilar - Anti-BSG, CD147 mAb - Research Grade

Introduction

Gavilimomab Biosimilar, also known as Anti-BSG, CD147 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original Gavilimomab drug. It is a research grade antibody that specifically targets the BSG (basigin) protein, also known as CD147, which is involved in various physiological and pathological processes. In this article, we will discuss the structure, activity, and potential applications of Gavilimomab Biosimilar in scientific research.

Structure of Gavilimomab Biosimilar

Gavilimomab Biosimilar is a fully humanized monoclonal antibody, meaning it is derived from human cells and has a structure similar to natural antibodies produced in the human body. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The variable regions of the antibody, which are responsible for binding to the target protein, are located at the tips of the heavy and light chains. The constant regions of the antibody are responsible for effector functions, such as activating the immune system.

Activity of Gavilimomab Biosimilar

Gavilimomab Biosimilar specifically targets the BSG protein, which is overexpressed in various cancers, including breast, lung, and colon cancer. BSG is also involved in the development and progression of inflammatory and autoimmune diseases. By binding to BSG, Gavilimomab Biosimilar can inhibit its function and disrupt its role in these diseases.

In addition to its direct effect on BSG, Gavilimomab Biosimilar also has an indirect anti-tumor activity. It can activate the immune system, particularly natural killer (NK) cells, to kill cancer cells. This is achieved through the antibody’s constant region, which can bind to immune cells and trigger their effector functions.

Applications of Gavilimomab Biosimilar in Research

Gavilimomab Biosimilar has potential applications in various areas of scientific research. Its ability to specifically target BSG makes it a valuable tool for studying the role of this protein in disease development and progression. It can also be used to investigate the mechanisms of action of BSG, as well as the potential therapeutic effects of targeting this protein.

In cancer research, Gavilimomab Biosimilar can be used to study the role of BSG in different types of cancer and to evaluate its potential as a therapeutic target. It can also be used in pre-clinical studies to assess the efficacy and safety of targeting BSG in cancer treatment.

In addition, Gavilimomab Biosimilar can be used in inflammatory and autoimmune disease research to investigate the role of BSG in these conditions and to evaluate the potential of targeting BSG as a treatment approach.

Conclusion

In summary, Gavilimomab Biosimilar is a research grade monoclonal antibody that specifically targets the BSG protein. Its structure, activity, and potential applications make it a valuable tool in scientific research, particularly in the fields of cancer and inflammatory diseases. Further studies and clinical trials are needed to fully understand the potential of Gavilimomab Biosimilar as a therapeutic agent and to bring it to the market as a biosimilar drug.